EXISTING EVIDENCE FOR SAFE USE OF HERBAL MEDICINES IN CHRONIC KINEY DISEASE

  • Mayuree Tangkiatkumjai Division of Clinical Pharmacy, Faculty of Pharmacy, Srinakharinwirot University, 63 Mu 7 Rangsit-Nakhonnayok Road, Nakhonnayok, Thailand 26120

Abstract

There has been a widespread use of herbal medicines in the last two decades, despite a lack of scientific evidence for their efficacy and safety. Health care professionals have expressed growing concerns about safety issues relating to use herbal medicine, particularly in patients with renal or liver insufficiency. This review will propose how to use existing evidence to suggest the safe use of herbal medicines in patients with renal insufficiency, as well as transferring toxicity findings of herbal medicines from animal studies to use in humans.

Safety information from postmarketing surveillance and case reports is likely to be the main information sources. However, there is little data relating to herbal medicines used by patients with chronic kidney disease. When human studies are lacking, animal studies can be seen as a substitute source of reliable information. An animal dose related to renal toxicity is used to calculate a theoretical human equivalent dose in order to estimate the toxicity in humans. However, this information should be used with caution. When herbal medicines used by people with renal insufficiency have, as yet, yielded no evidence of nephropathy, health care providers should regularly monitor kidney function of such people, together with their electrolytes. Observational studies are required to examine the renal adverse effects of herbal medicines.

 

Keywords: Herbal medicine, Nephrotoxicity, Evidence

Downloads

Download data is not yet available.

References

1. Wilkinson JM, Jelinek H. Complementary medicine use among attendees at a rural health screening clinic. Complementary Ther Clin Practice 2009;15:80-4.
2. Lee G, Charn T, Ng T. Complementary and alternative medicine use in patients with chronic diseases in primary care is associated with perceived quality of care and cultural beliefs. Fam Pract 2004;21:654-60.
3. World Health Organization. Traditional Medicine; 2008. Available from: URL: http://www.who.int/mediacentre/ factsheets/fs134/en/. [Last accessed on 1 Dec 2010].
4. Tangkiatkumjai M, Boardman H, Praditpornsilpa K, Walker DM. Prevalence of herbal and dietary supplement usage in Thai outpatients with chronic kidney disease: a cross-sectional survey. BMC Complementary Altern Med 2013;13:153.
5. Kara B. Herbal product use in a sample of turkish patients undergoing haemodialysis. J Clin Nurs 2009;18:2197-205.
6. Spanner ED, Duncan AM. Prevalence of dietary supplement use in adults with chronic renal insufficiency. J Renal Nutr 2005;15:204-10.
7. Grabe DW, Garrison GD. Comparison of natural product use between primary care and nephrology patients. Ann Pharmacother 2004;38:1169-72.
8. Barnes J, Abbot NC, Harkness EF, Ernst E. Articles on complementary medicine in the mainstream medical literature: an investigation of MEDLINE, 1966 through 1996. Arch Intern Med 1999;159:1721-5.
9. Gulati OP, Ottaway PB. Legislation relating to nutraceuticals in the European Union with a particular focus on botanical-sources products. Toxicology 2006;221:75-87.
10. European Food Safety Authority. Guidance on safety assessment of botanicals and botanical preparations intended for use as ingredients in food supplements. EFSA J 2009;7:1249-67.
11. World Health Organization. General guidelines for methodologies on research and evaluation of traditional medicine; 2000. Available from: URL: http://whqlibdoc.who.int/hq/2000/WHO_EDM_TRM_2000.1.pdf. [Last accessed on 11 Oct 2010].
12. Jiratchariyakul W, Mahady GB. Overview of botanical status in EU, USA, and Thailand. Evidence Based Complementary Altern Med 2013;21:480128.
13. Boullata JI, Nace AM. Safety issues with herbal medicine. Pharmacotherapy 2000;20:257-69.
14. Wen CP, Cheng TYD, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462293 adults in Taiwan. Lancet 2008;371:2173-82.
15. Hsieh CF, Huang SL, Chen CL, Chen WT, Chang HC, Wu ML, et al. Increased risk of chronic kidney disease among users of non-prescribed Chinese herbal medicine in Taiwan. Prev Med 2012;55:155-9.
16. Tsai SY, Tseng HF, Tan HF, Chien YS, Chang CC. End-stage renal disease in Taiwan: a case-control study. J Epidemiol 2009;19:169-76.
17. Lai MN, Lai JN, Chen PC, Hsieh SC, Hu FC, Wang JD. Risks of kidney failure associated with consumption of herbal products containing mu tong or fangchi: a population-based case-control study. Am J Kidney Dis 2010;55:507-18.
18. Guh JY, Chen HC, Tsai JF, Chuang LY. Herbal therapy is associated with the risk of CKD in adults not using analgesics in Taiwan. Am J Kidney Dis 2007;49:626-33.
19. Lin MY, Chiu YW, Lee CH, Yu HY, Chen HC, Wu MT, et al. Factors associated with CKD in the elderly and nonelderly population. Clin J Am Soc Nephrol 2013;8:33-40.
20. Ingsathit A, Thakkinstian A, Chaiprasert A, Sangthawan P, Gojaseni P, Kiattisunthorn K, et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant 2010;25:1567-75.
21. Ho PM, Peterson PN, Masoudi FA. Evaluating the evidence: Is there a rigid hierarchy? Circulation 2008;118:1675-84.
22. U. S. Food and Drug Administration. Oxy Elite Pro supplements recalled; 2013.
23. Canada Vigilance Adverse Reaction Online Database. Case presentation: Propolis and renal failure; 2009. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v19n1-eng. php#cp. [Last accessed on 20 Dec 2014].
24. Wechwithan S, Sriphiromya P, Suwankesawong W. Report of potential signals from thaivigibase during year 2007-2008. Drug Saf 2010;33:954.
25. WHO collaborating centre for international drug monitoring. National drug monitoring centres-drug safety issues. Adverse Reaction Newsletter. Uppsala; 1999. p. 4.
26. Haller CA, Kearney T, Bent S, Ko R, Benowitz NL, Olson K. Dietary supplement adverse events: report of a one-year poison center surveillance project. J Med Toxicol 2008;4:84-92.
27. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants od under-reporting of adverse drug reactionss: a systematic review. Drug Saf 2009;32:19-31.
28. Mader LS. Australian TGA launches online database of adverse events: low level of adverse events associated with herbal products; 2012. Available from: URL: http:// cms. herbalgram.org/ heg/volume9/10October/ TGAonline AEsdatabase. html?t= 1349285790. [Last accessed on 10 Jan 2015].
29. Luyckx VA. Nephrotoxicity of alternative medicine practice. Adv Chronic Kidney Dis 2012;19:129-41.
30. Arslan E, Sayin S, Demirbas S, Cakar M, Somak NG, Yesilkaya S, et al. A case study report of acute renal failure associated with Nigella sativa in a diabetic patient. J Integr Med 2013;11:64-6.
31. Lee KH, Jeong HS, Rhee H. A patient with minimal change disease and acute focal tubulointerstitial nephritis due to traditional medicine: a case report and small literature review. Explore 2014;10:319-23.
32. Lin YC, Chen YC, Chen TH, Chen HH, Tsai WJ. Acute kidney injury associated with hepato-protective Chinese herb-Pien tze huang. J Exp Clin Med 2011;3:184-6.
33. Kim EJ, Chen Y, Huang JQ, Li KM, Razmovski-Naumovski V, Poon J, et al. Evidence-based toxicity evaluation and scheduling of chinese herbal medicines. J Ethnopharmacol 2013;146:40-61.
34. Mueller BA, Scott MK, Sowinski KM, Prag KA. Noni juice (Morinda citrifolia): hidden potential for hyperkalemia? Am J Kidney Dis 2000;35:310-12.
35. de Oliveira RB, de Paula DAC, Rocha BA, Franco JJ, Gobbo-Neto L, Uyemura SA, et al. Renal toxicity caused by oral use of medicinal plants: the yacon example. J Ethnopharmacol 2011;133:434-41.
36. Movahedian A, Asgary S, Mansoorkhani HS, Keshvari M. Hepatotoxicity effect of some Iranian medicinal herbal formulation on rats. Adv Biomed Res 2014;3:12.
37. Zhou X, Yao Y. Unexpected nephrotoxicity in male ablactated rats induced by Cordyceps militaris: the involvement of oxidative changes. Evidence-Based Complementary Altern Med 2013. doi: 10.1155/2013/786528. [Article in Press].
38. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-61.
39. Baroni S, Suzuki-Kemmelmeier F, Caparroz-Assef SM, Cuman RKN, Bersani-Amado CA. Effect of crude extracts of leaves of Smallanthus sonchifolius (yacon) on glycemia in diabetic rats. Braz J Pharm Sci 2008;44:521-30.
40. National Kidney Foundation. Use of herbal supplements in chronic kidney disease; 2013. Available from: http://www.kidney.org/atoz/content/herbalsupp.cfm. [Last accessed on 17 Dec 2013].
41. National Drug Committee. National list of herbal medicine products. 1st ed. Bangkok: Ministry of Public Health Thailand; 2011.
42. Vanderperren B, Rizzo M, Angenot L, Haufroid V, Jadoul M, Hantson P. Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. Ann Pharmacother 2005;39:1353-7.
43. Albersmeyer M, Hilge R, Schrottle A, Weiss M, Sitter T, Vielhauer V. Acute kidney injury after ingestion of rhubarb: secondary oxalate nephropathy in a patient with type 1 diabetes. BMC Nephrol 2012;13:141.
44. Khan IA, Nasiruddin M, Haque SF, Khan RA. Evaluation of rhubarb supplementation in stages 3 and 4 of chronic kidney disease: a randomized clinical trial. Int J Chronic Dis 2014. doi.org/10.1155/2014/789340. [Article in Press].
Statistics
429 Views | 1337 Downloads
How to Cite
Tangkiatkumjai, M. “EXISTING EVIDENCE FOR SAFE USE OF HERBAL MEDICINES IN CHRONIC KINEY DISEASE”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 9, July 2015, pp. 30-34, https://innovareacademics.in/journals/index.php/ijpps/article/view/7096.
Section
Review Article(s)